More than 3.1 million bottles of over-the-counter eye drops sold at major retailers including Walgreens, CVS, Kroger and others have been recalled due to a lack of assurance of sterility during manufacturing, federal health officials said Friday.

3.1 Million Eye Drops Recalled at Walgreens, CVS Over Sterility
3.1 Million Eye Drops Recalled at Walgreens, CVS Over Sterility Concerns: FDA Class II Alert

The voluntary recall, initiated by Pomona, California-based K.C. Pharmaceuticals, Inc., covers approximately 3,111,072 bottles of various lubricant and redness-relief eye drops distributed nationwide. The U.S. Food and Drug Administration classified the action as a Class II recall, meaning use of the products may cause temporary or medically reversible adverse health consequences, or the probability of serious adverse health consequences is remote.

No illnesses or injuries have been reported in connection with the recall, according to FDA records posted March 31. The agency emphasized that the issue involves a failure to meet sterility standards in production rather than confirmed contamination in the finished products. Still, officials urged consumers to immediately stop using the affected drops and return them to the place of purchase for a refund or proper disposal.

The recalled eye drops were sold under dozens of store-brand and private-label names, including CVS Health, Walgreens, Kroger, Rite Aid, H-E-B, Harris Teeter, Dollar General, Leader, Good Sense and others. They were also distributed through Cardinal Health, military exchanges and additional outlets. Products include artificial tears, advanced relief formulas, redness relief drops and sterile eye drops in 0.5 fluid ounce (15 mL) bottles.

Specific quantities include 378,144 bottles of Sterile Eye Drops Original Formula containing tetrahydrozoline HCl 0.05%, along with hundreds of thousands of bottles each of Sterile Eye Drops AC, Eye Drops Advanced Relief and other variants. Lot codes and expiration dates vary, with many products carrying dates into 2026. Consumers should check the lot number and expiration on the bottle carton or label against the full list available on the FDA website.

Eye drops are considered sterile drug products, and any breach in manufacturing controls can introduce risk of bacterial or other microbial contamination. Such contamination could potentially lead to eye infections, irritation, vision problems or, in rare severe cases, more serious complications, particularly for people with compromised immune systems or pre-existing eye conditions.

Health experts advise anyone experiencing symptoms such as eye pain, redness that worsens, discharge, blurred vision or sensitivity to light after using these products to contact a healthcare provider promptly. The FDA recommends discarding unused portions rather than attempting to return opened bottles in some cases, though retailers may provide specific instructions.

This recall comes amid heightened scrutiny of over-the-counter ophthalmic products following several high-profile eye drop contamination incidents in recent years. Previous recalls involved bacterial and fungal outbreaks linked to certain imported artificial tears, prompting stricter oversight of manufacturing facilities.

K.C. Pharmaceuticals has not publicly detailed the specific manufacturing lapse that triggered the recall. The company initiated the action on or around March 3, with the FDA formally posting the enforcement report on March 31. Retailers began pulling affected inventory from shelves in recent weeks.

Walgreens and CVS, two of the largest pharmacy chains in the United States, confirmed they are cooperating fully with the recall. Spokespeople for both companies said they are notifying customers who purchased the products through loyalty programs or online and facilitating returns. Similar statements came from Kroger and other affected retailers.

Consumers with questions can contact K.C. Pharmaceuticals or check the FDA's MedWatch website for updates. The agency maintains a searchable database of recalls and provides detailed product photos and lot information to help identify affected items.

The scale of the recall — more than 3 million bottles — underscores the widespread popularity of affordable store-brand eye drops. Millions of Americans rely on these products daily for dry eye relief, allergy symptoms or minor irritation caused by screen time, contact lenses or environmental factors.

Ophthalmologists note that while most people tolerate minor manufacturing variations without issue, sterility is non-negotiable for products applied directly to the eyes. The eye's surface is particularly vulnerable because it lacks the robust immune defenses found in other parts of the body.

Dr. Elena Ramirez, a spokesperson for the American Academy of Ophthalmology, said in a statement that patients should err on the side of caution with any recalled medication. "If in doubt, throw it out," she advised. "There are many safe alternatives on the market, including preservative-free single-use vials that reduce contamination risk."

The recall does not affect prescription eye drops or major national brands produced under different manufacturing processes. Name-brand products from companies such as Refresh, Systane or Visine are not included unless specifically listed in the FDA notice.

Retail analysts said the financial impact on manufacturers and stores is likely significant but contained, given the voluntary nature and the ability to replace inventory quickly. Share prices for major pharmacy chains showed little movement Friday amid broader market activity.

For consumers, the practical steps are straightforward: examine medicine cabinets and bathroom drawers for any eye drop bottles purchased in recent months. Compare lot numbers and expiration dates against the FDA list. Return unaffected-looking but recalled products to the retailer. Consult a doctor or pharmacist if symptoms appear or if the drops were used regularly.

The FDA continues to monitor the situation and has not ruled out additional recalls or enforcement actions if further issues surface at the manufacturing facility. Officials stressed that proactive recalls like this one help prevent potential harm before problems escalate.

In the meantime, health authorities recommend proper storage and handling of all eye care products. Bottles should be kept tightly closed, stored at room temperature away from direct sunlight and never shared between users to minimize cross-contamination risks.

This latest development serves as a reminder of the importance of rigorous quality control in pharmaceutical manufacturing, even for seemingly simple over-the-counter items. As millions of bottles make their way back from store shelves and medicine cabinets, regulators and industry players will likely face renewed calls for enhanced inspection protocols.

Consumers seeking replacements should look for products labeled as sterile and check expiration dates carefully. Single-dose, preservative-free options may provide extra peace of mind for those concerned about contamination.

The full list of affected products, lot codes and distribution details remains available on the FDA's website under enforcement report event number 98533. Regular updates will be posted as retailers complete their returns and the investigation into the manufacturing process continues.

As spring allergy season ramps up and more people reach for relief, officials urged vigilance. With Easter weekend just passed and many families traveling or stocking up on household essentials, the timing of the public notice aims to reach as many consumers as possible before additional use occurs.

In summary, while the risk to any individual user appears low, the widespread distribution of these 3.1 million bottles warrants immediate action. Checking your eye drops today could prevent unnecessary discomfort or more serious issues tomorrow.